Hypera SA banner

Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 23.63 BRL -0.84% Market Closed
Market Cap: R$16.6B

Net Margin

11.8%
Current
Declining
by 6.5%
vs 3-y average of 18.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.8%
=
Net Income
R$823.9m
/
Revenue
R$7B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.8%
=
Net Income
R$823.9m
/
Revenue
R$7B

Peer Comparison

Country Company Market Cap Net
Margin
BR
Hypera SA
BOVESPA:HYPE3
16.6B BRL
Loading...
US
Eli Lilly and Co
NYSE:LLY
993.5B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
590.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
295.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
237.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
245.2B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
307.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.9B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
123.1B USD
Loading...

Market Distribution

In line with most companies in Brazil
Percentile
56th
Based on 634 companies
56th percentile
11.8%
Low
-6 965.9% — 2.1%
Typical Range
2.1% — 15.5%
High
15.5% — 1 493%
Distribution Statistics
Brazil
Min -6 965.9%
30th Percentile 2.1%
Median 8.9%
70th Percentile 15.5%
Max 1 493%

Hypera SA
Glance View

Market Cap
16.6B BRL
Industry
Pharmaceuticals

Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.

HYPE3 Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11.8%
=
Net Income
R$823.9m
/
Revenue
R$7B
What is Hypera SA's current Net Margin?

The current Net Margin for Hypera SA is 11.8%, which is below its 3-year median of 18.3%.

How has Net Margin changed over time?

Over the last 3 years, Hypera SA’s Net Margin has decreased from 23% to 11.8%. During this period, it reached a low of 11.1% on Jun 30, 2025 and a high of 23% on Sep 30, 2022.

Back to Top